Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: An observational study using primary care electronic health record data

被引:37
|
作者
Scott, Ian C. [1 ,2 ]
Whittle, Rebecca [1 ]
Bailey, James [1 ]
Twohig, Helen [1 ]
Hider, Samantha L. [1 ,2 ]
Mallen, Christian D. [1 ,2 ]
Muller, Sara [1 ]
Jordan, Kelvin P. [1 ]
机构
[1] Keele Univ, Primary Care Ctr Versus Arthrit, Sch Med, Keele, Staffs, England
[2] Midlands Partnership NHS Fdn Trust, Haywood Acad Rheumatol Ctr, Haywood Hosp, High Lane, Burslem, Staffs, England
来源
LANCET REGIONAL HEALTH-EUROPE | 2022年 / 23卷
基金
美国国家卫生研究院;
关键词
Rheumatoid arthritis; Psoriatic arthritis; Axial spondyloarthritis; Incidence; Prevalence; CLASSIFICATION CRITERIA; GLOBAL PREVALENCE; DIAGNOSES; VALIDITY;
D O I
10.1016/j.lanepe.2022.100519
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Contemporary data on rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (SpA) epidemiology in England are lacking. This knowledge is crucial to planning healthcare services. We updated algorithms defining patients with diagnoses of RA, PsA, and axial SpA in primary care and applied them to describe their incidence and prevalence in the Clinical Practice Research Datalink Aurum, an electronic health record (EHR) database covering similar to 20% of England. Methods Algorithms for ascertaining patients with RA, axial SpA, and PsA diagnoses validated in primary care EHR databases using Read codes were updated (to account for the English NHS change to SNOMED CT diagnosis coding) and applied. Updated diagnosis and synthetic disease-modifying anti-rheumatic drug code lists were devised by rheumatologists and general practitioners. Annual incidence/point-prevalence of RA, PsA, and axial SpA diagnoses were calculated from 2004 to 2020 and stratified by age/sex. Findings Point-prevalence of RA/PsA diagnoses increased annually, peaking in 2019 (RA 0 cent 779% [95% confidence interval (CI) 0.773, 0.784]; PsA 0.287% [95% CI 0.284, 0.291]) then falling slightly. Point-prevalence of axial SpA diagnoses increased annually (except in 2018/2019), peaking in 2020 (0.113% [95% CI 0.111, 0.115]). RA diagnosis annual incidence was higher between 2013-2019 (after inclusion in the Quality and Outcomes Framework, range 49.1 [95% CI 47. 7, 50.5] to 52. 1 [95% CI 50. 6, 53. 6]/100,000 person-years) than 2004-2012 (range 34. 5 [95% CI 33. 2, 35. 7] to 40. 0 [95% CI 38. 6, 41. 4]/100,000 person-years). Increases in the annual incidence of PsA/axial SpA diagnosis occurred following new classification criteria publication. Annual incidence of RA, PsA and axial SpA diagnoses fell by 40.1%, 67.4%, and 38.1%, respectively between 2019 and 2020, likely reflecting the COVID-19 pandemic's impact on their diagnosis. Interpretation Recorded RA, PsA, and axial SpA diagnoses are increasingly prevalent in England, underlining the importance of organising healthcare services to provide timely, treat-to-target care to optimise the health of > 1% of adults in England.
引用
收藏
页数:13
相关论文
共 34 条
  • [1] Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries
    Mease, Philip J.
    Liu, Mei
    Rebello, Sabrina
    Kang, Hyungjoo
    Yi, Esther
    Park, Yujin
    Greenberg, Jeffrey D.
    RHEUMATOLOGY AND THERAPY, 2019, 6 (04) : 529 - 542
  • [2] Analgesic prescribing in patients with inflammatory arthritis in England: an observational study using electronic healthcare record data
    Scott, Ian C.
    Bailey, James
    White, Chris
    Mallen, Christian D.
    Muller, Sara
    RHEUMATOLOGY, 2022, 61 (08) : 3201 - 3211
  • [3] Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries
    Philip J. Mease
    Mei Liu
    Sabrina Rebello
    Hyungjoo Kang
    Esther Yi
    Yujin Park
    Jeffrey D. Greenberg
    Rheumatology and Therapy, 2019, 6 : 529 - 542
  • [4] The epidemiology of psoriatic arthritis in the UK: a health intelligence analysis of UK Primary Care Electronic Health Records 1991-2020
    Druce, Katie L.
    Yimer, Belay Birlie
    Humphreys, Jennifer
    Njuki, Lucy N.
    Bourke, Darryl
    Li, Michael
    Ellis, Benjamin
    Zhang, Yuanyuan
    Bravo, Ramiro
    Hyrich, Kimme L.
    Verstappen, Suzanne M. M.
    Dixon, William G.
    McBeth, John
    RHEUMATOLOGY, 2023,
  • [5] High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry
    Fornaro, M.
    Righetti, G.
    Abbruzzese, A.
    Lopalco, G.
    Cacciapaglia, F.
    Anelli, M. G.
    Venerito, V.
    Iannone, F.
    CLINICAL RHEUMATOLOGY, 2021, 40 (09) : 3659 - 3665
  • [6] Physical Activity Assessment Using an Activity Tracker in Patients with Rheumatoid Arthritis and Axial Spondyloarthritis: Prospective Observational Study
    Jacquemin, Charlotte
    Servy, Herve
    Molto, Anna
    Sellam, Jeremie
    Foltz, Violaine
    Gandjbakhch, Frederique
    Hudry, Christophe
    Mitrovic, Stephane
    Fautrel, Bruno
    Gossec, Laure
    JMIR MHEALTH AND UHEALTH, 2018, 6 (01):
  • [7] Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study
    D'Angelo, Salvatore
    Tirri, Enrico
    Giardino, Angela Maria
    Mattucci-Cerinic, Marco
    Dagna, Lorenzo
    Santo, Leonardo
    Ciccia, Francesco
    Frediani, Bruno
    Govoni, Marcello
    Pallavicini, Francesca Bobbio
    Grembiale, Rosa Daniela
    Delle Sedie, Andrea
    Mule, Rita
    Cantatore, Francesco Paolo
    Foti, Rosario
    Gremese, Elisa
    Conigliaro, Paola
    Salaffi, Fausto
    Viapiana, Ombretta
    Cauli, Alberto
    Giacomelli, Roberto
    Arcarese, Luisa
    Guggino, Giuliana
    Russo, Romualdo
    Puenpatom, Amy
    Capocotta, Domenico
    Nacci, Francesca
    Anelli, Maria Grazia
    Picerno, Valentina
    Binetti, Corrado
    Iannone, Florenzo
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (14)
  • [8] Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries
    Egeberg, Alexander
    Roseno, Nana Aviaaja Lippert
    Aagaard, David
    Lorup, Erik Hillo
    Nielsen, Mia-Louise
    Nymand, Lea
    Kristensen, Lars Erik
    Thyssen, Jacob P.
    Thomsen, Simon Francis
    Cordtz, Rene Lindholm
    Loft, Nikolai
    Skov, Lone
    Bryld, Lars Erik
    Rasmussen, Mads Kirchheiner
    Hojgaard, Pil
    Kristensen, Salome
    Dreyer, Lene
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2022, 53
  • [9] A comparison of comorbidities and their risk factors prevalence across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis with focus on cardiovascular diseases: data from a single center real-world cohort
    Gula, Zofia
    Losinska, Katarzyna
    Kuszmiersz, Piotr
    Strach, Magdalena
    Nowakowski, Jaroslaw
    Biedron, Grzegorz
    Zimba, Olena
    Dyczek, Lukasz
    Haugeberg, Glenn
    Korkosz, Mariusz
    RHEUMATOLOGY INTERNATIONAL, 2024, : 2817 - 2828
  • [10] High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry
    M. Fornaro
    G. Righetti
    A. Abbruzzese
    G. Lopalco
    F. Cacciapaglia
    M. G. Anelli
    V. Venerito
    F. Iannone
    Clinical Rheumatology, 2021, 40 : 3659 - 3665